Celularity, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-09-01
- Employees
- 225
- Market Cap
- $66.1M
- Website
- http://www.celularity.com
CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Celularity Incorporated
- Registration Number
- NCT05218408
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 1
- Registration Number
- NCT05207722
- Locations
- 🇺🇸
Georgetown, Washington, District of Columbia, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Scripps Health, La Jolla, California, United States
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
- Conditions
- Interventions
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 3
- Registration Number
- NCT04489420
- Locations
- 🇺🇸
The Univeristy of Texas MD ANderson Cancer Center, Houston, Texas, United States
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 86
- Registration Number
- NCT04365101
- Locations
- 🇺🇸
UC Irvine, Irvine, California, United States
🇺🇸Multicare Health System, Tacoma, Washington, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 27
- Registration Number
- NCT04310592
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
- First Posted Date
- 2020-03-16
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 29
- Registration Number
- NCT04309084
- Locations
- 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Roswell Park Comprehensive Cancer Institute, Buffalo, New York, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 15
- Registration Number
- NCT02955550
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Washington Univ School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 10
- Registration Number
- NCT02781467
- Locations
- 🇺🇸
Roswell Park Cancer Center, Buffalo, New York, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Celularity Incorporated
- Target Recruit Count
- 26
- Registration Number
- NCT02552277
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Infinity Clinical Research, LLC, Sunrise, Florida, United States
🇺🇸Compass Research, LLC, Orlando, Florida, United States
Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
- Conditions
- Interventions
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- Celularity Incorporated
- Registration Number
- NCT02460081
- Locations
- 🇺🇸
University of Pennsylvania Health Systems, Philadelphia, Pennsylvania, United States